Abstract
The kinesin spindle protein (KSP, also known as Hs Eg5) plays an essential part in the proper separation of spindle poles and the correct formation of bipolar mitotic spindle during mitosis. Inhibition of this protein results in cells apoptosis followed by mitotic arrest and the formation of characteristic monoaster spindles. Compared with the traditional chemotherapeutic agents (taxanes, vinca alkaloids), KSP inhibitors (KSPi) will not lead to the neuropathic side effects, so KSP has become a novel and an attractive anticancer target. Accordingly, more and more interest has been focused on the development of high effective and selective KSPi. This review will focus on some kinds of KSPi on the basis of introducing structure and function of KSP.
Keywords: Kinesin, KSP, Uncompetitive Inhibitor, Competitive Inhibitor, Allosteric Inhibitor
Anti-Cancer Agents in Medicinal Chemistry
Title: Progress on Kinesin Spindle Protein Inhibitors as Anti-Cancer Agents
Volume: 8 Issue: 6
Author(s): Yingjie Zhang and Wenfang Xu
Affiliation:
Keywords: Kinesin, KSP, Uncompetitive Inhibitor, Competitive Inhibitor, Allosteric Inhibitor
Abstract: The kinesin spindle protein (KSP, also known as Hs Eg5) plays an essential part in the proper separation of spindle poles and the correct formation of bipolar mitotic spindle during mitosis. Inhibition of this protein results in cells apoptosis followed by mitotic arrest and the formation of characteristic monoaster spindles. Compared with the traditional chemotherapeutic agents (taxanes, vinca alkaloids), KSP inhibitors (KSPi) will not lead to the neuropathic side effects, so KSP has become a novel and an attractive anticancer target. Accordingly, more and more interest has been focused on the development of high effective and selective KSPi. This review will focus on some kinds of KSPi on the basis of introducing structure and function of KSP.
Export Options
About this article
Cite this article as:
Zhang Yingjie and Xu Wenfang, Progress on Kinesin Spindle Protein Inhibitors as Anti-Cancer Agents, Anti-Cancer Agents in Medicinal Chemistry 2008; 8 (6) . https://dx.doi.org/10.2174/187152008785133119
DOI https://dx.doi.org/10.2174/187152008785133119 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Evaluation Method of Mechanical Properties of Living NSCLC Cells Based on Nano-indentation
Current Nanoscience Drug Abuse Treatment through Gene Manipulation Using Nanomedicine
Current Pharmacogenomics and Personalized Medicine Proteomic Approaches in Plant Biology
Current Proteomics TNF-Related Apoptosis-Inducing Ligand (TRAIL) as a Pro-Apoptotic Signal Transducer with Cancer Therapeutic Potential
Current Pharmaceutical Design Combined Effect of Vaccinium nilgiriensis Bark Extract and 680nm Laser Irradiation in Inducing Breast Cancer Cell Death
Anti-Cancer Agents in Medicinal Chemistry Rational Design of 5-Aminolevulinic Acid Derivatives Aimed at Improving Photodynamic Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Clinical Trials in Children
Reviews on Recent Clinical Trials Personalized Diabetes and Cancer Medicine: A Rationale for Anti-Diabetic Nutrition (Bitter Melon) in a Supportive Setting
Current Cancer Therapy Reviews Diverse Functions of γ -secretase: Releasing Signaling Fragments and Deleterious Molecules
Current Enzyme Inhibition Targeting Cancer and Neuropathy with Histone Deacetylase Inhibitors:Two Birds with One Stone?
Current Cancer Drug Targets Pivotal Role of the Interaction Between Herbal Medicines and Gut Microbiota on Disease Treatment
Current Drug Targets Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry The Potential of Modulating Small RNA Activity In Vivo
Mini-Reviews in Medicinal Chemistry Viral Origins of Human Cancer
Current Medicinal Chemistry Drug Targets in Human T-Lymphotropic Virus Type 1 (HTLV-1) Infection
Infectious Disorders - Drug Targets The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
Current Cancer Drug Targets Editorial [Hot Topic: Anticancer Macromolecular Prodrugs in Clinical Trials - an Update (Guest Editor: Felix Kratz)]
Current Bioactive Compounds Non Pregnant Human Uterus as Source of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Herpes Simplex Encephalitis: From Virus to Therapy
Infectious Disorders - Drug Targets Bioprecursor Prodrugs: Molecular Modification of the Active Principle
Mini-Reviews in Medicinal Chemistry